際際滷

際際滷Share a Scribd company logo

Patient flow

Download as PPTX, PDF
M
Mohammad Haque

The document contains confidential information about patient flows for colorectal cancer (CRC), lung cancer (LCA), and other cancers (OCA). It provides data on the total number of patients for each cancer type, percentages that receive different treatments like surgery, chemotherapy, or no treatment, and the numbers of patients projected to be able to afford advanced treatments.

1 of 3
Download to read offline
Confidential for internal use only 1 PatientFlowCRC TotalCRCPatients 5,180 Operable (70%) 3,626 Inoperable(30%) 1,554 Go for Surgery (85%) 3,082 Go for FurtherTreatment 2,773 Systemic Chemotherapy(CT) (70%) 1,941 90% Oral CT(5%) 138 Radiotherapy (40%) 1,109 Affordable for advanced treatment 150 Ref.:Patientsno.Globocan2018, MarketResearch2015
Confidential for internal use only Patient flow - LCA Total LCA Patients 12,374 SCLC (20%) 2,473 NSCLC (80%) 9,900 Adenocarcinom (40%) 3,960 Large cell (30%) 2,970 Squamous cell (30%) 2,970 Surgery (15%) 594 Other treatment (55%) 2,178 Radiotherapy 871 Chemotherapy 1,306 Affordable for advanced 30 Ref.: Patient no. Globocan 2018, Market research 2015 No treatment (30%) 1,980
Confidential for internal use only Patient flow - OCA 3 OCA New Patinets 3,063 Operable (85%) 2,603 In-operable (15%) 459 Surgery (90%) 2,342 Continue treatment after 1,170 Further Treatment 1,630 Chemotherapy 965 Best supportive care 335 Affordable treatment 50 Ref.: Patients no. Globocan 2018, Market Research 2015 No treatment (20%) 330

More Related Content

Patient flow

  • 1. Confidential for internal use only 1 PatientFlowCRC TotalCRCPatients 5,180 Operable (70%) 3,626 Inoperable(30%) 1,554 Go for Surgery (85%) 3,082 Go for FurtherTreatment 2,773 Systemic Chemotherapy(CT) (70%) 1,941 90% Oral CT(5%) 138 Radiotherapy (40%) 1,109 Affordable for advanced treatment 150 Ref.:Patientsno.Globocan2018, MarketResearch2015
  • 2. Confidential for internal use only Patient flow - LCA Total LCA Patients 12,374 SCLC (20%) 2,473 NSCLC (80%) 9,900 Adenocarcinom (40%) 3,960 Large cell (30%) 2,970 Squamous cell (30%) 2,970 Surgery (15%) 594 Other treatment (55%) 2,178 Radiotherapy 871 Chemotherapy 1,306 Affordable for advanced 30 Ref.: Patient no. Globocan 2018, Market research 2015 No treatment (30%) 1,980
  • 3. Confidential for internal use only Patient flow - OCA 3 OCA New Patinets 3,063 Operable (85%) 2,603 In-operable (15%) 459 Surgery (90%) 2,342 Continue treatment after 1,170 Further Treatment 1,630 Chemotherapy 965 Best supportive care 335 Affordable treatment 50 Ref.: Patients no. Globocan 2018, Market Research 2015 No treatment (20%) 330